Kaiser Permanente's Vaccine Study Center and Division of Research, both based in Oakland, are conducting the trial in concert with Pfizer and BioNTech, which co-developed the vaccine that will be used in the trial.
The new schedule for the service that runs between the South Bay and the Sacramento area takes effect Monday and includes an increase from 16 to 22 weekday trips.